The overexpression of CCL2 chemokine in tumours like glioblastoma, bladder, prostate, breast, ovarian, gastric, melanoma and renal cell carcinoma facilitates the recruitment of CCR2+ LY6C+ M-MDSCs, causing a higher tumour load and reduced overall survival (49, 51). Here, CCL2 is linked to neoplasm.